Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...
Michelle Min, MD, MS, reviewed best practices for managing cutaneous lupus and discussed emerging therapies practitioners ...
Post hoc ICONIC phase 3 data show GLP-1 medications do not affect the efficacy, safety, or pharmacokinetics of icotrokinra in ...
Tralokinumab for AD was associated with sustained improvements in disease severity and no new safety signals at 12 months in a real-life study.
Congenital TORCH infections appear to be associated with an increased risk for intellectual disability and autism.
Dr Hamzavi discussed how to navigate conversations with patients with HS regarding common misconceptions, expectations with ...
The novel hyaluronic acid-based injection ANN0032 is noninferior to an active control treatment in patients with moderate to severe neck wrinkles.
Creams, sprays and washes that promise relief from genital herpes are easy to order online, but none of them are FDA-approved.
An active acupressure intervention offers clinical benefits for patients with rosacea when combined with pharmacotherapy.
Phase 3 ONWARD3 data demonstrate sustained skin clearance, pruritus relief, and quality of life improvements with ...
BRAVE-AA-PEDS data presented at FC26 show baricitinib maintained significant hair regrowth through 76 weeks in adolescents ...
Most patients with BRCA1/2 pathogenic variants who received navigation for cascade genetic testing completed genetic testing by 18 months.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results